GlassScriptPhysician profile
Ethan Michael Coucke
NPI 1487188710
$1,900.08
in general payments reported to CMS, 2019-2025
15 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $140 · 2021: $391 · 2023: $15.26 · 2024: $125 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.07 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $419.65 | 2019-2021 | |
| Glaxosmithkline, LLC. | $241.13 | 2024-2025 | Nucala |
| Janssen Pharmaceuticals, INC | $226.89 | 2019-2020 | |
| Pfizer INC. | $188.69 | 2019 | |
| Verona Pharma, INC. | $124.99 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $121.22 | 2019-2023 | Brilinta |
| Biogen, INC. | $114.22 | 2019 | |
| Inspire Medical Systems, INC. | $111.69 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $96.36 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $88.99 | 2025 | Opsumit, Uptravi |
| Allergan, INC. | $65.17 | 2019 | |
| Mallinckrodt Enterprises LLC | $31.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.17 | 2019 | |
| Boston Scientific Corporation | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Coucke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.